Cancer grading is the assessment of how abnormal cancer cells and their surrounding tissue appear under a microscope and, in many cancers, how closely the tumour resembles the normal tissue from which it arose. It is primarily a pathological assessment rather than an anatomical one. A pathologist examines tissue obtained through biopsy or surgery and evaluates features such as cellular differentiation, architectural organisation, nuclear abnormalities and, depending on the cancer, mitotic activity or other microscopic characteristics.
In broad terms, a low-grade tumour tends to retain more features of the normal tissue and often grows or spreads more slowly, whereas a high-grade tumour looks substantially more abnormal and is more likely to behave aggressively. The precise criteria are cancer-specific, so the word “grade” cannot be interpreted correctly without knowing which grading system applies to that tumour.
Differentiation is a central concept in grading. Well-differentiated cancer cells retain many structural and functional characteristics of the tissue from which they originated, whereas poorly differentiated cells have lost more of those characteristics. Undifferentiated cells may bear little resemblance to the original normal tissue. In many cancers, this loss of differentiation is associated with more aggressive biological behaviour, although the relationship is not absolute.
Pathologists may also assess how rapidly cells are dividing, the degree of nuclear atypia, necrosis and specific structural patterns. Some tumours have highly specialised grading criteria; for example, certain sarcomas, brain tumours, prostate cancers and breast cancers use systems that incorporate particular microscopic features or combinations of features rather than relying solely on general visual similarity to normal tissue.
Many cancers use grades numbered from 1 to 4, although the exact terminology varies. In a commonly used framework, grade 1 indicates a well-differentiated, relatively low-grade tumour; grade 2 indicates intermediate differentiation; grade 3 indicates poor differentiation and high-grade disease; and grade 4 indicates an undifferentiated high-grade tumour. Grade X may indicate that the grade cannot be assessed. These numbers should not be treated as a universal scale across all cancers.
A grade 2 tumour in one cancer is not necessarily biologically equivalent to a grade 2 tumour in another because the criteria used to assign the number differ. Some cancers use entirely different grading schemes, and some have specialised numerical systems that incorporate multiple microscopic measurements.
Grading differs fundamentally from staging. Staging describes the anatomical extent of a cancer, including the primary tumour, regional lymph nodes and distant spread. Grading describes microscopic tumour characteristics. A small, localized tumour can therefore be high grade, while a large or metastatic tumour can sometimes be relatively low grade. Stage and grade may correlate statistically in some cancers but measure different properties and should never be treated as interchangeable.
A useful conceptual distinction is that stage addresses how far the cancer has travelled or invaded, whereas grade addresses how abnormal the cancer cells appear and, indirectly, how aggressively they may behave. Clinical decisions often use both pieces of information alongside tumour subtype, molecular characteristics, biomarkers and the patient's overall health.
The grade is usually established from tissue obtained through biopsy or surgery. A pathologist prepares sections of the tissue, stains them and examines them microscopically, sometimes using immunohistochemistry or molecular tests to establish the tumour's identity and subtype before applying the appropriate grading criteria. The pathology report may contain several separate observations, including tumour type, differentiation, grade, invasion into surrounding tissue, lymphovascular invasion, margin status and lymph-node findings. These details can have different implications. Grade is therefore only one component of a pathology report rather than a complete summary of the tumour. In some cancers, additional molecular or genomic information can provide prognostic or treatment information that microscopic grading alone cannot capture.
Grade can influence treatment because high-grade tumours may be more likely to grow rapidly and recur, prompting consideration of treatments appropriate for biologically aggressive disease. However, treatment decisions are not made from grade alone. The cancer's site, stage, subtype, molecular features, resectability, expected response to treatment and patient factors all matter. Some high-grade tumours are particularly sensitive to chemotherapy or radiation because rapidly dividing cells can be vulnerable to these treatments, while other high-grade cancers require specialised approaches. Conversely, some low-grade cancers can still cause serious problems because of their location or because they may persist or recur over a long period. The prognostic significance of grade is therefore cancer-specific and must be interpreted within the appropriate clinical framework.
A common misconception is that grade and stage form a single scale of cancer severity, with grade 4 necessarily meaning stage IV. They do not. “Grade 4” describes a microscopic characteristic in systems that use four grades, while “stage IV” generally describes distant spread. Another misconception is that a low-grade tumour is automatically harmless. Low-grade cancers are still malignant and can invade tissues, recur or metastasise depending on their type. Conversely, a high-grade cancer is not necessarily untreatable. Grade describes probability and biological tendencies, not an inevitable outcome. The terminology “well differentiated”, “moderately differentiated”, “poorly differentiated” and “undifferentiated” can therefore be more informative than the number alone, particularly when interpreted alongside the specific tumour type and pathology criteria.
Cancer grading is an evolving field because microscopy is increasingly complemented by molecular pathology. Tumours that look similar under a microscope can have different genetic alterations and treatment sensitivities, while tumours that look somewhat different can share important biological drivers. Consequently, contemporary pathology often combines morphology with immunohistochemistry, molecular testing and biomarker assessment. Nevertheless, microscopic grading remains important for many cancers because it provides clinically useful information about differentiation and biological behaviour. The most accurate interpretation of a reported grade requires knowing the exact cancer type, the grading system used and the other pathological findings.
